US FDA Approved Jemincare to Initiate Clinical Trial of Neutralizing Antibody JMB2002

Corporate Breaking News

Home : US FDA Approved Jemincare to Initiate Clinical Trial of Neutralizing Antibody JMB2002

Apr 02 2021	US FDA Approved Jemincare to Initiate Clinical Trial of Neutralizing Antibody JMB2002
SHANGHAI, April 2, 2021 /PRNewswire/ -- On March 31, 2021, Jemincare group announced that their anti-SARS-CoV-2 neutralizing antibody, JMB2002, independently developed by Jemincare Shanghai Research Center, was approved by FDA for clinical trial in the United States. Preclinical data...


Source:https://www.prnewswire.com:443/news-releases/us-fda-approved-jemincare-to-initiate-clinical-trial-of-neutralizing-antibody-jmb2002-301261264.html

Related News
» SOF-11 Klimt CAI S.a.r.l. (« BidCo »), une filiale contrôlée de Starwood Capital Group, annonce que la condition préalable à la clôture de l'offre publique d'achat de CA Immobilien Anlagen AG (« CA Immo ») a été remplie » Yili to Help Westland's 'Westgold' Go Global